Antibody Engineering & Therapeutics Asia 2024
Kyoto, Japan
October 21–23, 2024
Genedata Japan will be taking part in the Antibody Engineering & Therapeutics Asia 2024 held in Kyoto, Japan.
Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, stratification of clinical trial subjects, and quality control of biologicals.
For more information about Genedata solutions, please contact info(at)genedata.com (English) or japan(at)genedata.com (Japanese).
Recommended Oral Presentation
Scientific Briefing: Faster Time to Market through Digital Innovation in Biologics Research and Development
Mizue Hisano, Ph.D., Scientific Business Consultant, Genedata AG
Wednesday, October 23 | 8:05 - 8:35 am
Biologics research and development present unique challenges in data management and analytics. Complex logistics, massive data streams from unique HT processes, and diverse modalities such as antibodies and bispecifics and cell and gene therapies require on-going advancement of fit-for-purpose digital technology and automation approaches. Digital innovation can significantly accelerate biologics R&D and it is increasingly seen as a competitive differentiator. We present use cases showing how biopharma and biotech organizations digitalize and automate their biologics workflows today and how they leverage having full traceability and data integrity for data sciences and machine learning.
Recommended Poster Presentation
An Automated High Throughput Engineering Platform for AI-Supported Developability Predictions
Mizue Hisano, Ph.D., Scientific Business Consultant, Genedata AG
Combinatorial selection strategies and advances in protein and nucleotide engineering have been successful in generating novel large-molecule therapeutics. Bi- and multi-specific antibodies, antibody drug conjugates (ADCs), chimeric antigen receptors (CARs), engineered T-cell receptors (TCRs), and other formats offer new approaches to treatment. However, the efficient design, production, and multi-dimensional characterization represent a major challenge, especially when creating those highly engineered therapeutic candidates in high throughput. Here, we demonstrate how the Genedata Biologics® platform enables a fully automated workflow for next-gen modalities, integrating all steps from selection, molecular biology, expression, purification, and analytics. Built-in workflows for automated in silico molecule assembly mechanisms allow efficient design of large panels of novel biomolecules. Dedicated tools for pooled cloning deconvolution and automated chain pairing recovery automate the generation of tens of thousands of molecule variants that are then tested for drug-like properties. Data from multi-parametric screening is captured in the system’s highly structured database and systematically analyzed to evaluate the candidates under consideration of all meta-data, genomic, and phenotype information. We demonstrate the platform’s capabilities by illustrating a fully integrated developability and manufacturability assessment using a novel AI/ML approach for large panels of bi-specific molecules. Further, we illustrate how the platform can be used to automate the full range of innovative modalities, including CAR-Ts, AAVs, and mRNA-LNPs.
